Brucine, a plant derived alkaloid inhibits inflammatory angiogenesis in a murine sponge model

Biomedicine and Preventive Nutrition

Volumn 1, Issue 3, 2011, Pages 180-185

  Agrawal, S S ^a   Saraswati, S ^a   Mathur, R ^a   Pandey, M ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

CD 31; Microvessel density; TGF ; TNF ; VEGF

Indexed keywords

BRUCINE; CD31 ANTIGEN; HEMOGLOBIN BETA CHAIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GRANULATION TISSUE; GRANULOMA; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; MALE; MICROVESSEL DENSITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; WEIGHT REDUCTION;

EID: 83655182295     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2011.06.014     Document Type: Article

References (32)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Alibini A., Tosetti F., Benelli R., Douglas D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005, 65:10637-10641.
3. Yin W., Wang T.S., Yin F.Z., Cai B.C. Analgesic and anti-inflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnox nux-vomica. J Ethnopharmacol 2003, 88:205-214.
4. Tripathi Y.B. Free radicals in Ayurveda. Ancient Sci Life 1998, 17:158-168.
5. Tripathi Y.B., Chaurasia S. Interaction of Strychnos nux-vomica products and iron: with reference to lipid peroxidation. Phytomedicine 2000, 7:523-528.
6. Philippe G., Angenot L., Tits M., Frederich M. About the toxicity of some Strychnos species and their alkaloids. Toxicon 2004, 44:405-416.
7. Deng X.K., Yin W., Li W.D., Yin F.Z., Lu X.Y., Zang X.C., et al. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism. J Ethnopharmacol 2006, 106:179-186.
8. Yin W., Deng X.K., Li W.D., Yin F.Z., Lu X.Y., Zang X.C., et al. The cytotoxicity induced by Strychnos nux-vomica proceeds via apoptosis by Cox 2 and caspase-3 in SMMC 7221 cells. Food Chem Toxicol 2007, 45:1700-1708.
9. Rao P.S., Ramanadham M., Prasad M.N.V. Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line-RPMI 8226. Food Chem Toxicol 2009, 47:283-288.
10. Edward R.H., Sarmenta S.S., Hass G.M. Stimulation of granulation tissue growth by tissue extracts; study by intramuscular wounds in rabbits. Arch Path 1960, 69:286-292.
11. Andrade S.P., Fan T.P.D., Lewis G.P. Quantitative in vivo studies on angiogenesis in rat sponge model. Br J Exp Path 1987, 68:755-756.
12. Passaniti A., Taylor A.M., Pili R., Guo Y., Long P.V., Haney J.A., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992, 67:519-528.
13. Lage A.P., Andrade S.P. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc Res 2000, 59:278-285.
14. Hlkatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002, 94:883-893.
15. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
16. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-249.
17. Klagsbrun M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996, 7:259-270.
18. Belo A.V., Barcelos L.S., Ferreira M.A.N.D., Teixeira M.M., Andrade S.P. Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sci 2004, 74:2827-2837.
19. Bergheim I., Luyendyk J.P., Steele C., et al. Metformin prevents endotoxininduced liver injury after partial hepatectomy. J Pharmacol Exp Ther 2006, 316:1053-1061.
20. Ferreira M.A.N.D., Barcelos L.S., Campos P.P., Vasconcelos A.C., Teixeira M.M., Andrade S.P. Sponge-induced angiogenesis and inflammation in PAF receptor- deficient mice (PAFR-KO). Br J Pharmacol 2004, 141:1185-1192.
21. Campos P.P., Bakhle Y.S., Andrade S.P. Mechanisms of wound healing responses in lupus-prone New Zealand white mouse strain. Wound Repair Reg 2008, 16:416-424.
22. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 21:4368-4380.
23. Plouet J., Schilling J., Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989, 8:3801-3806.
24. Nicosia R.F., Nicosia S.V., Smith M. Vascular endothelial growth factor, platelet-derived growth factor and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994, 145:1023-1029.
25. Phillips G.D., Stone A.M., Jones B.D., Schultz J.C., Whitehead R.A., Knighton D.R. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1995, 8:961-965.
26. Tolentino M.J., Miller J.W., Gragoudas E.S., Chatzistefanou K., Ferrara N., Adamis A.P. VEGF is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol 1996, 114:964-970.
27. Connolly D., Olander J., Heuvelman D., Nelson R., Monsell R., Siegel N., et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989, 264:20017-20024.
28. Appleton I., Brown N.J., Willis D., et al. The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J Pathol 1996, 180:90-94.
29. Chen H.X., Gore-Langton R.E., Cheson B.D. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001, 15:1023-1026.
30. Yamaoka M., Masaki T., Sudo K., Shino A., Fujita T. Acceleration of wound healing by recombinant human basic fibroblast growth factor in a rat sponge-implantation model. Jpn J Inflamm 1991, 11:65-72.
31. Toi M., Hoshima S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85:1045-1049.
32. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858-863.